Steigerwald Gordon & Koch Inc. Buys 13 Shares of Eli Lilly and Company (NYSE:LLY)

Steigerwald Gordon & Koch Inc. increased its stake in Eli Lilly and Company (NYSE:LLY) by 0.4% during the third quarter, Holdings Channel.com reports. The firm owned 3,132 shares of the company’s stock after purchasing an additional 13 shares during the quarter. Steigerwald Gordon & Koch Inc.’s holdings in Eli Lilly and Company were worth $2,776,000 as of its most recent filing with the SEC.

A number of other institutional investors have also bought and sold shares of the business. Guardian Asset Advisors LLC increased its stake in Eli Lilly and Company by 1.7% in the 3rd quarter. Guardian Asset Advisors LLC now owns 3,423 shares of the company’s stock worth $3,035,000 after buying an additional 56 shares in the last quarter. Morton Capital Management LLC CA grew its position in Eli Lilly and Company by 72.2% in the third quarter. Morton Capital Management LLC CA now owns 720 shares of the company’s stock worth $638,000 after acquiring an additional 302 shares in the last quarter. BSN CAPITAL PARTNERS Ltd purchased a new position in Eli Lilly and Company in the third quarter worth about $16,785,000. Clarus Wealth Advisors bought a new stake in Eli Lilly and Company in the third quarter worth about $659,000. Finally, Adirondack Trust Co. lifted its stake in Eli Lilly and Company by 2.1% in the third quarter. Adirondack Trust Co. now owns 4,682 shares of the company’s stock worth $4,148,000 after purchasing an additional 95 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 0.8 %

Shares of NYSE LLY traded down $7.24 during midday trading on Thursday, reaching $912.50. 487,563 shares of the stock were exchanged, compared to its average volume of 3,007,116. The company has a 50 day simple moving average of $906.72 and a 200 day simple moving average of $850.80. The stock has a market capitalization of $867.24 billion, a P/E ratio of 134.49, a PEG ratio of 2.78 and a beta of 0.42. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. Eli Lilly and Company has a twelve month low of $547.61 and a twelve month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, beating the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. The firm had revenue of $11.30 billion during the quarter, compared to the consensus estimate of $9.83 billion. As a group, equities analysts expect that Eli Lilly and Company will post 16.49 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on LLY shares. Bank of America lifted their price target on shares of Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the company a “buy” rating in a research note on Friday, August 9th. BMO Capital Markets boosted their price objective on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Barclays increased their price target on Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 10th. Citigroup started coverage on Eli Lilly and Company in a research report on Friday, September 13th. They set a “buy” rating and a $1,060.00 price target on the stock. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $1,025.00 target price on shares of Eli Lilly and Company in a research note on Thursday, October 3rd. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average target price of $979.29.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.